Pacific Biosciences of California Toekomstige groei

Future criteriumcontroles 1/6

Pacific Biosciences of California zal naar verwachting groeien in winst en omzet met respectievelijk 33.2% en 19.6% per jaar. De winst per aandeel zal naar verwachting groeien met 35.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -33.7% zijn.

Belangrijke informatie

33.2%

Groei van de winst

35.3%

Groei van de winst per aandeel

Life Sciences winstgroei	18.4%
Inkomstengroei	19.6%
Toekomstig rendement op eigen vermogen	-33.7%
Dekking van analisten	Good
Laatst bijgewerkt	12 Nov 2024

Recente toekomstige groei-updates

Recent updates

Pacific Biosciences' Cost Cuts Won't Offset Rising Competition

Nov 12

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Nov 07

Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Oct 16

Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Sep 20

Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing

Aug 21

Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

Jul 02

We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Jun 08

Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas

Jun 03

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

Apr 25

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Apr 16

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Mar 19

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Feb 08

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Feb 01

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Dec 18

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

Nov 13

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Aug 28

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Jul 31

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Jul 06

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

May 25

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Mar 29

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Feb 26

Winst- en omzetgroeiprognoses

NasdaqGS:PACB - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	255	-165	-86	-43	11
12/31/2025	192	-198	-122	-108	13
12/31/2024	156	-357	-250	-184	13
9/30/2024	173	-394	-240	-233	N/A
6/30/2024	189	-400	-261	-253	N/A
3/31/2024	200	-297	-249	-240	N/A
12/31/2023	201	-307	-268	-259	N/A
9/30/2023	170	-309	-274	-262	N/A
6/30/2023	146	-319	-275	-260	N/A
3/31/2023	134	-321	-296	-279	N/A
12/31/2022	128	-314	-280	-263	N/A
9/30/2022	137	-299	-249	-234	N/A
6/30/2022	140	-206	-224	-212	N/A
3/31/2022	135	-175	-176	-167	N/A
12/31/2021	131	-181	-117	-111	N/A
9/30/2021	122	-37	-97	-94	N/A
6/30/2021	106	-77	-73	-71	N/A
3/31/2021	92	-59	-80	-79	N/A
12/31/2020	79	29	18	20	N/A
9/30/2020	80	-46	14	16	N/A
6/30/2020	83	-51	15	16	N/A
3/31/2020	90	-53	21	22	N/A
12/31/2019	91	-84	-81	-78	N/A
9/30/2019	82	-115	-82	-79	N/A
6/30/2019	79	-111	-78	-76	N/A
3/31/2019	76	-109	-76	-73	N/A
12/31/2018	79	-103	-68	-66	N/A
9/30/2018	84	-93	-71	-68	N/A
6/30/2018	89	-90	N/A	-71	N/A
3/31/2018	88	-93	N/A	-70	N/A
12/31/2017	93	-92	N/A	-68	N/A
9/30/2017	94	-90	N/A	-60	N/A
6/30/2017	96	-86	N/A	-58	N/A
3/31/2017	97	-79	N/A	-64	N/A
12/31/2016	91	-74	N/A	-68	N/A
9/30/2016	101	-57	N/A	-56	N/A
6/30/2016	90	-37	N/A	-56	N/A
3/31/2016	94	-31	N/A	-44	N/A
12/31/2015	93	-32	N/A	-48	N/A
9/30/2015	73	-49	N/A	-63	N/A
6/30/2015	80	-60	N/A	-53	N/A
3/31/2015	67	-67	N/A	-59	N/A
12/31/2014	61	-66	N/A	-51	N/A
9/30/2014	53	-64	N/A	-51	N/A
6/30/2014	40	-76	N/A	-26	N/A
3/31/2014	34	-77	N/A	-29	N/A
12/31/2013	28	-79	N/A	-30	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat PACB de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat PACB de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat PACB de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van PACB ( 19.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van PACB ( 19.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat PACB binnen 3 jaar verliesgevend zal zijn.

Pacific Biosciences of California Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 47%

Price target decreased by 7.8% to US$3.92

Consensus EPS estimates upgraded to US$0.93 loss, revenue downgraded

Price target decreased by 7.2% to US$5.40

Price target decreased by 16% to US$8.44

Consensus revenue estimates decrease by 11%, EPS upgraded

Recent updates

New minor risk - Shareholder dilution

Pacific Biosciences' Cost Cuts Won't Offset Rising Competition

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

PacBio Unveils the Vega System

PacBio Announces SPRQ Chemistry for Revio Sequencing Systems

Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

President recently sold US$173k worth of stock

President notifies of intention to sell stock

Chief Operating Officer recently sold US$63k worth of stock

Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing

Chief Operating Officer notifies of intention to sell stock

Consensus EPS estimates fall by 47%

Price target decreased by 7.8% to US$3.92

Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024

Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index

Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas

Consensus EPS estimates upgraded to US$0.93 loss, revenue downgraded

Price target decreased by 7.2% to US$5.40

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

New major risk - Share price stability

Price target decreased by 16% to US$8.44

Consensus revenue estimates decrease by 11%, EPS upgraded

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Price target decreased by 11% to US$9.41

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions

Insider recently bought US$176k worth of stock

Full year 2023 earnings: EPS misses analyst expectations

President recently sold US$481k worth of stock

President notifies of intention to sell stock

Price target decreased by 9.2% to US$11.17

Full year 2023 earnings: EPS misses analyst expectations

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024

PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions

Chief Operating Officer recently sold US$241k worth of stock

Price target decreased by 7.7% to US$11.92

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board

Price target decreased by 7.3% to US$12.67

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee

Price target decreased by 10% to US$13.92

Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors

Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

President recently sold US$980k worth of stock

President notifies of intention to sell stock

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Chief Operating Officer recently sold US$287k worth of stock

Chief Operating Officer notifies of intention to sell stock

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million.

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?